Eribulin mesylate
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Breast Cancer
Trial Timeline
Jun 1, 2013 → Jul 1, 2015
NCT ID
NCT01961544About Eribulin mesylate
Eribulin mesylate is a approved stage product being developed by Eisai for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01961544. Target conditions include Breast Neoplasms, Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Neoplasms